Live Breaking News & Updates on Biontech

Stay informed with the latest breaking news from Biontech on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Biontech and stay connected to the pulse of your community

COVID-19 vaccine: GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

GlaxoSmithKline (GSK) has filed a lawsuit against Pfizer and BioNTech in Delaware federal court, alleging infringement of GSK's patents related to messenger RNA (mRNA) technology in their COVID-19 vaccines. GSK claims that Pfizer and BioNTech's Comirnaty vaccines violate its patents developed over a decade ago. Pfizer has expressed confidence in its intellectual property (IP) position and intends to vigorously defend against the claims. GSK is open to licensing its patents on reasonable terms to ensure continued patient access to the vaccines.

Glaxosmithkline , Covid-19-vaccine , Pfizer , Biontech , Mrna-technology , Delaware-federal-court , Mrna-vaccine-innovations , Pfizer-spokesperson , Moderna , Novartis ,

Brokerages Set BioNTech SE (NASDAQ:BNTX) PT at $120.40

Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been assigned a consensus rating of “Hold” from the ten ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and four have assigned a buy recommendation to the company. […]

Canaccord-genuity-group , Biontech-company-profile , Jpmorgan-chase-co , First-horizon-advisors-inc , Covestor-ltd , Frazier-financial-advisors , Get-free-report , Financial-advisors , First-horizon-advisors , Get-free , Biontech

BioNTech SE (NASDAQ:BNTX) Given Average Recommendation of "Hold" by Brokerages

BioNTech SE (NASDAQ:BNTX – Get Free Report) has been assigned an average rating of “Hold” from the ten ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and four have assigned a buy recommendation to the […]

First-horizon-advisors-inc , Covestor-ltd , Goldman-sachs-group , Frazier-financial-advisors , Canaccord-genuity-group , Get-free-report , Genuity-group , Financial-advisors , First-horizon-advisors , Get-free , Biontech

Lester Murray Antman dba SimplyRich Takes Position in BioNTech SE (NASDAQ:BNTX)

Lester Murray Antman dba SimplyRich purchased a new stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund purchased 2,391 shares of the company’s stock, valued at approximately $252,000. Several other hedge funds and other institutional investors have also recently modified their holdings of BNTX. US […]

Lester-murray-antman , Canaccord-genuity-group , Us-bancorp , Great-west-life-assurance-co , Sei-investments-co , Holdings-channel , Cibc-world-market-inc , Biontech-company-profile , Blackrock-inc , Jpmorgan-chase-co , Free-report , West-life-assurance

BioNTech SE (NASDAQ:BNTX) Short Interest Up 5.5% in March

BioNTech SE (NASDAQ:BNTX – Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 3,080,000 shares, a growth of 5.5% from the February 29th total of 2,920,000 shares. Currently, 1.3% of the shares of the stock are short […]

Langfristige-investoren , Nasdaq , Goldman-sachs-group-inc , Virtu-financial , Financial-services-group-inc , Canaccord-genuity-group , Biontech-company-profile , Jpmorgan-chase-co , Pricet-rowe-associates-inc , Get-free-report , Genuity-group , Services-group

BioNTech SE (NASDAQ:BNTX) Given Consensus Rating of "Hold" by Brokerages

BioNTech SE (NASDAQ:BNTX – Get Free Report) has been assigned a consensus rating of “Hold” from the ten ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company. […]

Us-bancorp , Great-west-life-assurance-co , Biontech-company-profile , Goldman-sachs-group , Nasdaq , Blackrock-inc , Canaccord-genuity-group , Sei-investments-co , Jpmorgan-chase-co , Cibc-world-market-inc , Get-free-report

BioNTech SE (NASDAQ:BNTX) Receives $142.43 Consensus Target Price from Analysts

Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have earned an average recommendation of “Hold” from the ten brokerages that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and four have given a buy recommendation to the company. […]

Canaccord-genuity-group , Jpmorgan-chase-co , Frazier-financial-advisors , Covestor-ltd , Eagle-bay-advisors , Biontech-company-profile , Get-free-report , Marketbeat-ratings , Genuity-group , Financial-advisors , Get-free

JPMorgan Chase & Co. Lowers BioNTech (NASDAQ:BNTX) Price Target to $90.00

BioNTech (NASDAQ:BNTX – Free Report) had its price objective reduced by JPMorgan Chase & Co. from $99.00 to $90.00 in a research note published on Friday, Benzinga reports. They currently have an underweight rating on the stock. Other research analysts also recently issued research reports about the stock. HC Wainwright dropped their target price on […]

Langfristige-investoren , Jpmorgan-chase-co , Financial-services-group-inc , Goldman-sachs-group-inc , Pricet-rowe-associates-inc , Canaccord-genuity-group , Virtu-financial , Goldman-sachs-group , Free-report , Genuity-group , Services-group , Sachs-group

BioNTech (NASDAQ:BNTX) PT Lowered to $90.00

BioNTech (NASDAQ:BNTX – Free Report) had its target price trimmed by JPMorgan Chase & Co. from $99.00 to $90.00 in a research report report published on Friday morning, Benzinga reports. The firm currently has an underweight rating on the stock. A number of other brokerages also recently commented on BNTX. BMO Capital Markets lowered their […]

Frazier-financial-advisors , Eagle-bay-advisors , Goldman-sachs-group , Canaccord-genuity-group , Jpmorgan-chase-co , Covestor-ltd , Biontech-company-profile , Free-report , Stock-down , Financial-advisors , Get-free-report

JPMorgan Chase & Co. Cuts BioNTech (NASDAQ:BNTX) Price Target to $90.00

BioNTech (NASDAQ:BNTX – Free Report) had its price objective cut by JPMorgan Chase & Co. from $99.00 to $90.00 in a report released on Friday morning, Benzinga reports. They currently have an underweight rating on the stock. BNTX has been the topic of several other reports. HC Wainwright lowered their price objective on BioNTech from […]

Renaissance-technologies , Blackrock-inc , Baillie-gifford-co , Jpmorgan-chase-co , Canaccord-genuity-group , Goldman-sachs-group , Envestnet-asset-management-inc , Free-report , Genuity-group , Asset-management , Get-free-report